Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Temozolomide in the Treatment of Brain Metastasis From Non-Small-Cell Lung Cancer (Study P02143)(COMPLETED)
This study has been completed.
First Received: May 1, 2002   Last Updated: May 31, 2006   History of Changes
Sponsor: Schering-Plough
Information provided by: Schering-Plough
ClinicalTrials.gov Identifier: NCT00034697
  Purpose

Brain metastases from solid tumors are diagnosed in more than 300,000 patients annually. Nonsmall cell lung cancer accounts for the majority of CNS mets. Treatment with whole brain radiation and steroids will improve neurologic symptoms in about 50% of patients although survival is short. This study will test the safety and efficacy of temozolomide in combination with radiation therapy in the treatment of patients with brain mets form nonsmall cell lung cancer.


Condition Intervention Phase
Metastases, Neoplasm
Carcinoma, Non-Small-Cell Lung
Brain Neoplasms
Drug: temozolomide
Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase II Study of Temozolomide (SCH 52365) in Subjects With Brain Metastasis From Non-Small-Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Schering-Plough:

Estimated Enrollment: 60
Study Start Date: June 2001
Estimated Study Completion Date: November 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic confirmation of non-small-cell lung cancer
  • Stable systemic disease
  • Maximum of one prior chemotherapy regimen for metastatic systemic disease
  • Radiotherapy for local control or palliative bony lesions is allowed
  • Karnofsky of greater than or equal to 70%
  • Adequate hematologic, renal and liver function

Exclusion Criteria:

  • Patients eligible for surgery of the brain
  • Any previous chemotherapy for the brain metastasis
  • Chemotherapy within 4 weeks or previous temozolomide
  • Prior radiotherapy to the brain
  • Radiation therapy to greater than 50% of the bone marrow
  • Insufficient recovery from previous therapies
  • Active nonmalignant systemic disease
  • Inability to take oral medication
  • Pregnant or nursing women
  • Non use of adequate contraceptive techniques, negative urine pregnancy test is required
  • Known AIDS related illness
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Study ID Numbers: P02143
Study First Received: May 1, 2002
Last Updated: May 31, 2006
ClinicalTrials.gov Identifier: NCT00034697     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Schering-Plough:
Brain mets
non-small cell lung cancer

Additional relevant MeSH terms:
Thoracic Neoplasms
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Central Nervous System Neoplasms
Brain Diseases
Neoplastic Processes
Neoplasms by Site
Pathologic Processes
Respiratory Tract Diseases
Lung Neoplasms
Therapeutic Uses
Neoplasm Metastasis
Alkylating Agents
Nervous System Neoplasms
Respiratory Tract Neoplasms
Neoplasms by Histologic Type
Nervous System Diseases
Central Nervous System Diseases
Temozolomide
Pharmacologic Actions
Carcinoma
Brain Neoplasms
Neoplasms
Lung Diseases
Antineoplastic Agents, Alkylating
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on November 27, 2009